Top Banner
91

Who theme final

Jun 25, 2015

Download

Education

mary jacob

world health day theme presentation
theme: vectro borne diseases
slogan : small bite; big threat..
symposium conducted on thrissur govt college of nursing by MSc nursing students...
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Who theme final
Page 2: Who theme final
Page 3: Who theme final

WORLD HEALTH DAY

APRIL 7th 2014

Page 4: Who theme final

WORLD HEALTH ORGANIZATION

• Specialized agency of the United Nations. (UN)• Concerned with International public health.• Established on 7 April 1948.• Headquarters in Geneva, Switzerland.• Headed by Dr. Margaret

Chan.

Page 5: Who theme final

• The WHO organizes international, regional and local events on the day related to a particular theme.

• The designated day for celebrating the World Heath Day is 7th April.

• Each year a theme is selected that highlight a priority area of public health.

Page 6: Who theme final
Page 7: Who theme final

GENERAL REASONS FOR CELEBRATING WORLD HEALTH

DAY• focus on increasing the life expectancy by

promoting good health & healthier living habits

• Control of diseases through wide range of preventive measures by preventing modes of transmission

• Support all health authorities on global basis to make their own efforts for the public health problems to enhance better life

Page 8: Who theme final

OBJECTIVES

• To increase the public awareness of various causes and prevention of diseases

• To provide detail knowledge of getting prevented from various diseases and complications

• To encourage most vulnerable group of people to frequently check their health status and follow treatment regimen

• To promote self care among people

Page 9: Who theme final

Contd..

• To motivate the worldwide health authorities to make their own efforts in creating the healthy environments

• To protect families living in the disease vulnerable areas

• To teach travelers an how to get protected from vectors borne diseases while travelling

Page 10: Who theme final

CELEBRATIONS

• Governments, Non governments, NGO ‘s including various health organize programmes related to public health issues and awareness

• Highlights activities and supports through the media reports like press release , news , posters etc

• Pledges, Debates, Art competitions• Theme presentation.

Page 11: Who theme final

WORLD HEALTH DAY THEME 2014

“VECTOR BORNE

DISEASES”

Page 12: Who theme final

IMPORTANCE

• World’ s fastest growing vector borne diseases is dengue with a 30 fold increase in disease incidence over the last 50years

• Drastic increase in global population at risk of malaria between 2000 and 2012

• In 2012, there were an estimated 207 million cases of malaria and 627000 malaria deaths

• Mostly risky cases were found in Africa and South East Asia

Page 13: Who theme final

GOALS …

• Better protection from vector borne diseases• Universal access to prevention and

treatment

Page 14: Who theme final
Page 15: Who theme final

SLOGAN

Page 16: Who theme final
Page 17: Who theme final

• Mosquitoes, flies, ticks and bugs may be a threat to your health – and that of your family - at home and when travelling.

• This is the message of this year’s World Health Day, on 7 April. This short video highlights simple measures we can take to protect ourselves.

Page 18: Who theme final
Page 19: Who theme final

HIGHLIGHTS OF THE THEME

• Know before you travel• Preventing vector borne diseases• Preventing and controlling vector borne

diseases

Page 20: Who theme final

KNOW BEFORE YOU TRAVEL

Page 21: Who theme final

POSTERS FOR THE THEME

Page 22: Who theme final
Page 23: Who theme final
Page 24: Who theme final

PREVENTING VECTOR BORNE DISEASES

• Preventing vector borne diseases being the prime end of WHO.

• Mainly focusing on vectors and vector borne diseases.

Page 25: Who theme final
Page 26: Who theme final

VECTORS

•Mosquitoes• Ticks• Snails• Sand flies

Page 27: Who theme final
Page 28: Who theme final

VECTOR BORNE DISEASES

• Dengue fever• Malaria• Leishmaniasis• Schistosomiasis• Chagas disease• Lymphatic filariasis

Page 29: Who theme final
Page 30: Who theme final
Page 31: Who theme final

PREVENTING AND CONTROLLING VECTOR BORNE DISEASES

• Simple, cost-effective interventions like insecticide-treated bed nets and indoor spraying have already saved millions of lives,”- Dr Margaret Chan, WHO Director-General.

• “No one in the 21st century should die from the bite of a mosquito, a sandfly, a blackfly or a tick.”

Page 33: Who theme final

DENGUE FEVER

• According to the World Health Organisation (WHO), more than 2.5 billion people in the world are now at risk of suffering from dengue.

• The Aedes aegypti mosquito is the primary vector of dengue.

Page 34: Who theme final
Page 35: Who theme final
Page 36: Who theme final
Page 37: Who theme final
Page 38: Who theme final
Page 39: Who theme final
Page 40: Who theme final
Page 41: Who theme final
Page 42: Who theme final
Page 43: Who theme final

SIGNS AND SYMPTOMS OF DENGUE FEVER

• Sudden-onset fever• Headache (typically located behind

the eyes) • Muscle and joint pains• Rash

Page 44: Who theme final
Page 45: Who theme final
Page 46: Who theme final

PREVENTION AND CONTROL

• Preventing mosquitoes by environmental management and modification.

• Disposing of solid waste properly.• Covering, emptying and cleaning of domestic

water storage containers on a weekly basis.• Using of personal household protection.

Page 47: Who theme final

WHO RESPONSE

• Supports countries in the confirmation of outbreaks.

• Provides technical support and guidance to countries.

• Supports countries to improve their reporting systems.

• Provides training on clinical management, diagnosis and vector control.

Page 48: Who theme final

Contd..

• Applying appropriate insecticides to water storage outdoor containers

• Improving community participation.• Applying insecticides as space spraying during

outbreaks.• Active monitoring and surveillance of vectors

Page 49: Who theme final

Contd..

• Formulates evidence-based strategies and policies.

• Develops new tools, including insecticide products and application technologies.

• Gathers official records of dengue and severe dengue from over 100 member states.

• Publishes guidelines and handbooks for case management, dengue prevention and control.

Page 50: Who theme final

MALARIA

• Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected anopheles mosquitoes.

• In 2012, malaria caused an estimated 627 000 deaths (with an uncertainty range of 473 000 to 789 000), mostly among African children.

Page 51: Who theme final
Page 52: Who theme final
Page 53: Who theme final
Page 54: Who theme final

MALARIA

Page 55: Who theme final

PREVENTION AND CONTROL

Vector control• Insecticide-treated mosquito nets

(ITNs)• Indoor spraying with residual

insecticides

Page 56: Who theme final

WHO RESPONSE

• setting, communicating and promoting the adoption of evidence-based norms, standards, policies, technical strategies, and guidelines;

• keeping independent score of global progress;• developing approaches for capacity building,

systems strengthening, and surveillance;• identifying threats to malaria control and

elimination as well as new areas for action.

Page 57: Who theme final

LEISHMANIASIS

• Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of infected sandflies

• An estimated 1.3 million new cases and 20000 to 30 000 deaths occur annually.

Page 58: Who theme final

CLASSIFICATION

• Cutaneous leishmaniasis• Mucocutaneous leishmaniasis • Visceral leishmaniasis

Page 59: Who theme final
Page 60: Who theme final

TYPES

• The cutaneous form: presents with skin ulcers• Mucocutaneous form: presents with ulcers of

the skin, mouth and nose• Viceral form: starts with skin ulcers and than

latter presents with fever, low red blood cells, and a large spleen and liver.

Page 61: Who theme final
Page 62: Who theme final
Page 63: Who theme final

MUCOCUTANEOUS LEISHMANIASIS

Page 64: Who theme final

PREVENTION AND CONTROL

• Early diagnosis and effective case management

• Vector control • Effective disease surveillance • Control of reservoir hosts • Social mobilization and strengthening

partnerships

Page 65: Who theme final

Contd..• Providing technical support to build

sustainable, effective surveillance system and epidemic preparedness and response.

• Strengthening collaboration and coordination• Monitoring the global leishmaniasis situation,

trends and measure progress in the disease control, and financing

• Promoting research on effective leishmaniasis control

Page 66: Who theme final

WHO RESPONSE

• Supporting national leishmaniasis control programmes.

• Raising awareness and advocacy on the global burden of leishmaniasis.

• Promoting equitable access to health services for disease prevention and case management.

• Developing evidence-based policy guidelines, strategies and standards.

Page 67: Who theme final

SCHISTOSOMIASIS• Schistosomiasis is an acute and chronic disease

caused by parasitic worms.• The number of people reported to have been

treated for schistosomiasis in 2012 was 42.1 million and 249 million taken preventive treatment

• People become infected when larval forms of the parasite released by freshwater snails penetrate the skin during contact with infested water.

Page 68: Who theme final

Prevention and control

• Large-scale treatment of at-risk population groups, access to safe water, improved sanitation, hygiene education and snail control.

• The WHO strategy for schistosomiasis control focuses on reducing disease through periodic, targeted treatment with praziquantel

Page 69: Who theme final

WHO RESPONSE

• Preventive chemotherapy in consultation with collaborating centres

• WHO develops technical guidelines and tools for use by national control programmes.

• Increased access to praziquantel and resources for implementation

Page 70: Who theme final

CHAGAS DISEASE

• Chagas disease or American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite, Trypanosoma cruzi.

• About 7 million to 8 million people are estimated to be infected worldwide, mostly in Latin America where Chagas disease is endemic.

Page 71: Who theme final

PREVENTION AND CONTROL

• Spraying of houses and surrounding areas with residual insecticides.

• House improvements to prevent vector infestation.

• Personal preventive measures such as bednets.

Page 72: Who theme final

Contd…

• To kill the parasite, Chagas disease can be treated with benznidazole and also nifurtimox

• There is no vaccine for Chagas disease. • Vector control is the most effective method of

prevention

Page 73: Who theme final

Contd..

• Good hygiene practices in food preparation, transportation, storage and consumption.

• Screening of blood donors.• Testing of organ, tissue or cell of donors and

receivers.• Screening of newborns and other children of

infected mothers to provide early diagnosis and treatment.

Page 74: Who theme final

WHO RESPONSE

• Strengthening world epidemiological surveillance and information systems.

• Preventing transmission by blood transfusion and organ transplantation.

• Promoting the identification of diagnostic tests for screening and diagnosis of infections.

• Expanding secondary prevention of congenital transmission and case management of congenital and non-congenital infections.

Page 75: Who theme final

LYMPHATIC FILARIASIS

• Nearly 1.4 billion people in 73 countries worldwide are threatened by lymphatic filariasis or elephantiasis.

• Over 120 million people are currently infected, with about 40 million disfigured and incapacitated by the disease.

Page 76: Who theme final

WHO’s strategy is based on 2 key components:• stopping transmission through large-scale

annual treatment of all eligible people in an area or region where infection is present.

• alleviating the suffering caused by lymphatic filariasis through increased morbidity management and disability prevention activities.

Page 77: Who theme final

WHO RESPONSE• Large-scale treatment (mass drug

administration)Albendazole (400 mg) together with ivermectin (150-200 mcg/kg) or with diethylcarbamazine citrate (DEC) (6 mg/kg).

• Morbidity management and disability prevention

• Vector control

Page 78: Who theme final
Page 79: Who theme final
Page 80: Who theme final
Page 81: Who theme final
Page 82: Who theme final
Page 83: Who theme final
Page 84: Who theme final
Page 85: Who theme final
Page 86: Who theme final
Page 87: Who theme final
Page 88: Who theme final
Page 89: Who theme final
Page 90: Who theme final
Page 91: Who theme final

THANK YOUTHANK YOU